Compare Amgen, Inc. (AMGN) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Sea Limited — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Sea Limited trades at $111.52 (market cap $68.07B). The key difference: Amgen, Inc. is far larger — about 2.9× Sea Limited's market cap, and Amgen, Inc. pays a 2.77% dividend while Sea Limited pays none. Which is the better fit depends on your goals.
| AMGN | SE | |
|---|---|---|
Market Cap | $196.12B | $68.07B |
Sector | Health | Media |
52-Week High | $388.16 | $196.50 |
52-Week Low | $271.18 | $78.16 |
Enterprise Value | $241.41B | $61.12B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Sea Limited (SE) trades at $111.14, up 1.86% on the day, near its resistance level of $112. The stock shows strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarterly earnings have been mixed. Technical indicators are bullish on moving averages but show overbought conditions with RSI above 78. Analyst sentiment remains positive with a consensus price target of $131.
Outlook: Growth prospects are supported by expanding digital services in Southeast Asia, but risks include competitive pressures and execution challenges. The stock's high P/E of 43.76 suggests premium valuation, requiring sustained earnings growth to justify current levels. Near-term performance may hinge on Q2 2026 earnings versus expectations of $0.834 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
